chemotherapyneutropeniagranulocyte colony stimulating factorbiosimilarsZarsioхимиотерапиянейтропениягранулоцитарный колониестимулирующий факторбиоаналогЗарсио1.1.http://www.usatoday.com / news / health /2008.12.09.cancer_N.htm.http://www.usatoday.com / news / health /2008.12.09.cancer_N.htm.2.2. Bodey G. P., Buckley M., Sathe Y. S. et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328.40.Bodey G. P., Buckley M., Sathe Y. S. et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328.40.3.3. Chang J. Chemotherapy dose reduction and delay in clinical practice: Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 2000;36(suppl 1):S11.S14.Chang J. Chemotherapy dose reduction and delay in clinical practice: Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 2000;36(suppl 1):S11.S14.4.4. Lyman G. H., Dale D. C., Crawford J. Incidence and Predictors of Low Dose- Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices. J Clin Oncol 2003;21:4524.31.Lyman G. H., Dale D. C., Crawford J. Incidence and Predictors of Low Dose- Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices. J Clin Oncol 2003;21:4524.31.5.5. Morrison V. A., Picozzi V., Scott S. et al. The impact of age on delivered dose intensity and hospitalization for febrile neutropenia in patients with intermediate-grade non- Hodgkin's lymphoma receiving initial chop chemotherapy: a risk factor analysis. Clin Lymphoma 2001;2:47.56.Morrison V. A., Picozzi V., Scott S. et al. The impact of age on delivered dose intensity and hospitalization for febrile neutropenia in patients with intermediate-grade non- Hodgkin's lymphoma receiving initial chop chemotherapy: a risk factor analysis. Clin Lymphoma 2001;2:47.56.6.6. Lyman G. Commentary Undertreatment of Cancer Patients With Chemotherapy Is a Global Concern. J Oncol Pract 2008;4(3):114.5.Lyman G. Commentary Undertreatment of Cancer Patients With Chemotherapy Is a Global Concern. J Oncol Pract 2008;4(3):114.5.7.7. Sculier J. P., Weerts D., Klastersky J. Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapy. Eur J Cancer Clin Oncol 1984;20:55.60.Sculier J. P., Weerts D., Klastersky J. Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapy. Eur J Cancer Clin Oncol 1984;20:55.60.8.8. Kuderer N. M., Cosler L., Crawford J. et al. Cost and mortality associated with febrile neutropenia in adult cancer patients (abstr. 998). Proc Am Soc Clin Oncol 2002;21:250a.Kuderer N. M., Cosler L., Crawford J. et al. Cost and mortality associated with febrile neutropenia in adult cancer patients (abstr. 998). Proc Am Soc Clin Oncol 2002;21:250a.9.9. Lo N., Cullen M. Antibiotic prophylaxis in chemotherapyinduced neutropenia: time to reconsider. Hematol Oncol 2006;24(3):120.5.Lo N., Cullen M. Antibiotic prophylaxis in chemotherapyinduced neutropenia: time to reconsider. Hematol Oncol 2006;24(3):120.5.10.10. McColl S.R., Paquin R., Menard C, Beaulieu A. D. Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte / macrophage colony-stimulating factor and tumor necrosis factor alpha. J Exp Med 1992;176(2):593.8.McColl S.R., Paquin R., Menard C, Beaulieu A. D. Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte / macrophage colony-stimulating factor and tumor necrosis factor alpha. J Exp Med 1992;176(2):593.8.11.11. Crawford J., Ozer H., Stoller R. et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325(3):164.70.Crawford J., Ozer H., Stoller R. et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325(3):164.70.12.12. Trillet-Lenoir V., Green J., Manegold C. et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A(3):319.24.Trillet-Lenoir V., Green J., Manegold C. et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A(3):319.24.13.13. Crommelin D. J., Bermejo T., Bissig M. et al. Pharmaceutical evaluation of biosimilars: important differences from generic low-molecular weight pharm. Eur J Hosp Pharm Sci 2005;1:11.7.Crommelin D. J., Bermejo T., Bissig M. et al. Pharmaceutical evaluation of biosimilars: important differences from generic low-molecular weight pharm. Eur J Hosp Pharm Sci 2005;1:11.7.14.14. Aapro M., Ludwig H., Gascon P. Prophylaxis of chemotherapy-induced febrile neutropeniawith biosimilar filgrastim: description of patients, treatment patterns and outcomes in the monitor-GCSF study. Support Care Cancer 2014;22(Suppl 1):S221.Aapro M., Ludwig H., Gascon P. Prophylaxis of chemotherapy-induced febrile neutropeniawith biosimilar filgrastim: description of patients, treatment patterns and outcomes in the monitor-GCSF study. Support Care Cancer 2014;22(Suppl 1):S221.15.15. Gascon P., Fuhr U., Sorgel F. et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol 2010;21:1419.29.Gascon P., Fuhr U., Sorgel F. et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol 2010;21:1419.29.16.16. Green M. D., Koelbl H., Baselga J. et al. A randomized double-blind multicenter phase III study of fixed-dose singleadministration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29.35.Green M. D., Koelbl H., Baselga J. et al. A randomized double-blind multicenter phase III study of fixed-dose singleadministration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29.35.17.17. Holmes F. A., OЃfShaughnessy J. A., Vukelja S. et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III / IV breast cancer. J Clin Oncol 2002;20:727.31.Holmes F. A., OЃfShaughnessy J. A., Vukelja S. et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III / IV breast cancer. J Clin Oncol 2002;20:727.31.18.18. Tesch H., Abenhardt W., Dietz L. et al. Non-interventional study HEXAFIL: G-CSF use in accordance to guidelines? 54th Annual Meeting of the American Society of Hematology (ASH 2012) Congress, December 8.11, Atlanta, GA, USA.Tesch H., Abenhardt W., Dietz L. et al. Non-interventional study HEXAFIL: G-CSF use in accordance to guidelines? 54th Annual Meeting of the American Society of Hematology (ASH 2012) Congress, December 8.11, Atlanta, GA, USA.19.19. Lefrere F., Ribeil J. A., Turner M. et al. Biosimilar compared with originator filgrastim for related-donor allogeneic stem cell mobilisation: a prospective-historical control study. Presented at the 55th Annual Meeting of the American Society of Haematology (ASH), New Orleans, LA, USA, December 7.10, 2013.Lefrere F., Ribeil J. A., Turner M. et al. Biosimilar compared with originator filgrastim for related-donor allogeneic stem cell mobilisation: a prospective-historical control study. Presented at the 55th Annual Meeting of the American Society of Haematology (ASH), New Orleans, LA, USA, December 7.10, 2013.20.20. Aapro M., Cornes P., Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy- induced febrile neutropenia. J Oncol Pharm Pract 2012;18:171.Aapro M., Cornes P., Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy- induced febrile neutropenia. J Oncol Pharm Pract 2012;18:171.